Rheumatic diseases were once thought of as rare on the African continent. But one session during the 2018 ACR/ARHP Annual Meeting, will dispel this perception—with three speakers presenting on the state of rheumatic disease in Africa…
Celiac Awareness Makes a Difference for Rheumatology Patients
Celiac disease and gluten sensitivity are difficult to diagnose, but they affect multiple systems and are associated with other autoimmune diseases. Lan Chen, MD, PhD, believes better testing and clearer education will be a gamechanger for celiac patients…
Researchers Probe the Role of Fat Cells in Inflammation
AMSTERDAM—It’s been many years since adipose tissue came to be appreciated not just as a store of energy, but also as a regulator of metabolism and an important player in immune function. Rheumatology researchers continue to drill down into the role of fat cells in the search for mechanisms that could reveal targets for the…
Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection
AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…
Trial Data Reveals the Limitations of Steroids in Giant Cell Arteritis Therapy
AMSTERDAM—Just how seldom prednisone is successful at inducing remission in giant cell arteritis (GCA), despite such a long history of use for the disease, is one of the many lessons to emerge from the data in the GiACTA trial, said the principal investigator of the trial, which is the largest ever in GCA and is…
Researchers Release Proposed Lupus Criteria, & Pathogenesis Findings
AMSTERDAM—Newly proposed systemic lupus erythematosus (SLE) classification criteria and new findings on SLE pathogenesis are two ways in which researchers and clinicians are getting a better grasp on the heterogeneous disease. The criteria and findings were discussed this June in a session at EULAR: the Annual European Congress of Rheumatology. ‘Paradigm Shift’ Sindhu Johnson, MD,…
Researchers Fight Cellular Senescence, Low-Grade Inflammation
AMSTERDAM—Low-grade inflammation in older adults can impede immune responsiveness, and researchers have shed light on how this happens. They have developed a short-term treatment that blocks inflammation and boosts the immune response, an expert said at EULAR: the Annual European Congress of Rheumatology. The findings were presented in a session on cellular senescence related to…
Researchers Work Toward Early ID & Treatment of Rheumatoid Arthritis
AMSTERDAM—Early identification and treatment of rheumatoid arthritis (RA) are two of the most pressing concerns in the field, an expert said at EULAR: the Annual European Congress of Rheumatology. He described the latest efforts to identify patients at risk of RA development and insights on quick referral to rheumatologists. Karim Raza, BM, BCh, PhD, Arthritis…
A 46-Year Study Traces the Lupus Death Rate from 1968–2013
A study published in Annals of Internal Medicine in December 2017 looked at trends in lupus mortality over a 46-year period. The researchers say they set out to close some knowledge gaps. “There [was] a knowledge gap relating to the large differences we see in death rates from one study to another, which could have…
Immune Checkpoint Inhibitors & Immune-Related Adverse Events
Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 342
- Next Page »